Angiotensin II subtype 1 receptor blockers and renal function

Archives of Internal Medicine

Volumn 161, Issue 12, 2001, Pages 1492-1499

  Toto, R ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

BLOOD PRESSURE REGULATION; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; HORMONE RECEPTOR INTERACTION; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

EID: 0034912836     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.161.12.1492     Document Type: Review

References (78)

1. Disease statistics
2. Prevalence of hypertension in the US adult population: Results from the Third National Health and Nutrition Examination Survey, 1988-1991
3. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
4. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population: Data from the Health Examination Surveys, 1960 to 1991
5. Priority area 15: Heart disease and stroke
6. Incidence and prevalence of ESRD
7. High blood pressure and diabetes mellitus: Are all antihypertensive drugs created equal?
8. Hypertension in patients with chronic renal disease
9. Changes in renal function associated with drugs or placebo therapy of human hypertension
10. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function: Results from the Hypertension Detection and Follow-up Study
11. Blood pressure and end-stage renal disease in men
12. Progression of diabetic nephropathy: A focus on arterial pressure level and methods of reduction
13. The effect of treatment on the vascular deterioration associated with hypertension, with particular emphasis on renal function
14. Blood pressure control, proteinuria, and the progression of renal disease: The Modification of Diet in Renal Disease Study
15. "Strict" blood pressure control and progression of renal disease in hypertensive nephrosclerosis
16. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency
17. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy
18. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
19. Effect of enalapril on the progression of chronic renal failure: A randomized controlled trial
20. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy
21. Longterm comparison between captopril and nifedipine in the progression of renal insufficiency
22. Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure
23. Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: A controlled double-blind trial
24. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy
25. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39
26. Understanding the nature of renal disease progression
27. How to assess glomerular function and damage in humans
28. How far since Ellis? The Manchester study of glomerular disease
29. Does an adequate control of blood pressure protect the kidney in essential hypertension?
30. Multiple pathways of angiotensin production in the blood vessel wall: Evidence, possibilities and hypotheses
31. Should we aim at tissue renin-angiotensin systems?
32. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system?
33. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy
34. The paradox of the low-renin state in diabetic nephropathy
35. Pharmacologic interruption of the renin-angiotensin system and the kidney: Differential responses to angiotensin-converting enzyme and renin inhibition
36. Renoprotection and renin-angiotensin system blockade in diabetes mellitus
37. Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease
38. Efficacy and tolerability of losartan in hypertensive patients with renal impairment
39. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)
40. Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension
41. The effects of valsartan and captopril on reducing microalbuminuria in patients with type 2 diabetes mellitus: A placebo-controlled trial
42. ACE inhibition or angiotensin receptor blockade: Impact on potassium in renal failure
43. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy
44. Safety of the combination of valsartan and benazepril in patients with chronic renal disease
45. Bradykinin-mediated effects of ACE inhibition
46. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects
47. Antihypertensive therapy with MK 421: Angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade
48. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria
49. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria
50. Hypertension in patients with diabetes: Strategies for drug therapy to reduce complications
51. Hypertension in patients with diabetes: Overcoming barriers to effective control
52. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy
53. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: A meta-analysis of randomized trials
54. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria
55. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
56. Angiotensin-II-receptors: New targets for antihypertensive therapy
57. 2 receptor: Fact, fancy and fantasy
58. Angiotensin II receptor inhibition: A new therapeutic principle
59. 1 receptor antagonists
60. Accelerated fibrosis and collagen deposition develop in the renal interstitium of angiotensin type 2 receptor null mutant mice during ureteral obstruction
61. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass
62. Role of angiotensin II and bradykinin in experimental diabetic nephropathy: Functional and structural studies
63. Effect of candesartan cilexetil (TCV-116) in rats with chronic renal failure
64. Effects of angiotensin inhibitors on renal injury and angiotensin receptor expression in early hypertensive nephrosclerosis
65. The angiotensin receptor antagonist, irbesartan, reduces renal injury in experimental chronic renal failure
66. 1 receptor blockade on blood pressure and the renin-angiotensin system in spontaneously hypertensive rats of the stroke prone strain
67. Prevention of renal injury in diabetic MWF rats by angiotensin II antagonism
68. Effects of eprosartan on glomerular injury in rats with reduced renal mass
69. Effects of antihypertensive treatment on vascular remodeling in essential hypertensive patients
70. Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy
71. Angiotensin II receptor antagonists
72. ABCD-2V: Appropriate blood pressure control in diabetes - Part 2 with valsartan
73. Quality of life in patients with NIDDM and nephropathy at baseline: The losartan renal protection study (RENAAL)
74. Multicenter collaborative trial of angiotensin II receptor antagonism on morbidity, mortality and renal function in hypertensive type Il diabetic patients with nephropathy
75. Optimizing antihypertensive therapy in patients with diabetic nephropathy
76. Angiotensin-II receptor antagonists: Their place in therapy
77. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy: A review of the literature and pathophysiology
78. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial - The Losartan Heart Failure Survival Study ELITE II